Preprint Hypothesis Version 1 Preserved in Portico This version is not peer-reviewed

The Lysosome: A Potential Therapeutic Juncture between the COVID-19 Pandemic and Niemann-Pick Type C Disease

Version 1 : Received: 20 March 2020 / Approved: 24 March 2020 / Online: 24 March 2020 (03:07:06 CET)

A peer-reviewed article of this Preprint also exists.

Ballout RA, Sviridov D, Bukrinsky MI, Remaley AT. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. The FASEB Journal. 2020;00:1–12. https://doi.org/10.1096/fj.20200 0654R Ballout RA, Sviridov D, Bukrinsky MI, Remaley AT. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. The FASEB Journal. 2020;00:1–12. https://doi.org/10.1096/fj.20200 0654R

Journal reference: The FASEB Journal 2020
DOI: 10.1096/fj.202000654R

Abstract

In the face of the newly emergent COVID-19 pandemic, researchers around the world are racing to identify efficacious drugs capable of preventing or treating its infection. They are doing that by testing already available and approved antimicrobials for their rapid repurposing against COVID-19. Using the data emerging on the comparable efficacy of various compounds having different mechanisms of action and indications, I suggest in this report, their potential mechanistic convergence. Specifically, I highlight the lysosome as a key possible therapeutic target for COVID-19, proposing one of the lysosomal storage disorders, Niemann-Pick type C disease (NPC), as a prototypical condition with inherent resistance or an “unfavorable” host cell environment for viral propagation. The included reasoning evolves from previously generated data in NPC, along with the emerging data on COVID-19. The aim of this report is to suggest that pharmacological induction of a “transient” NPC-like lysosomal dysfunction, could hold answers for targeting the ongoing COVID-19 pandemic.

Subject Areas

coronavirus; SARS-CoV-2; lysosomal storage diseases; lipid rafts; cholesterol; angiotensin-converting enzyme-2 (ACE2); cathepsins

Comments (1)

Comment 1
Received: 6 May 2020
Commenter: Rami Ballout
The commenter has declared there is no conflict of interests.
Comment: For the published and peer-reviewed manuscript corresponding to this preprint, please refer to: https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.202000654R
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.